21 results on '"Oude Elberink, Hanneke N. G."'
Search Results
2. Hereditary Alpha Tryptasemia: Validation of a Single-Well Multiplex Digital Droplet PCR Assay in a Cohort of Symptomatic Patients
- Author
-
Alheraky, Abdulrazzaq, primary, Wierenga, Albertus T J, additional, Simpelaar, Arjan, additional, Hesp, Lucy B, additional, Minovic, Isidor, additional, Bagheri, Niusha, additional, Roozendaal, Caroline, additional, Span, Lambert F R, additional, Oude Elberink, Hanneke N G, additional, Kema, Ido P, additional, and Mulder, André B, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study
- Author
-
Oude Elberink, Hanneke N. G., Jalving, Mathilde, Dijkstra, Hilda, and van de Ven, Annick A. J. M.
- Published
- 2020
- Full Text
- View/download PDF
4. Detection of clonal mast cell disease in wasp venom allergic patients with normal tryptase
- Author
-
Onnes, Merel C., primary, Alheraky, Abdulrazzaq, additional, Nawijn, Martijn C., additional, Sluijter, Tim E., additional, Mulder, André B., additional, Arends, Suzanne, additional, and Oude Elberink, Hanneke N. G., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Pharmacology, particle deposition and drug administration techniques of intranasal corticosteroids for treating allergic rhinitis
- Author
-
Rollema, Corine, primary, van Roon, Eric N., additional, van Boven, Job F. M., additional, Hagedoorn, Paul, additional, Klemmeier, Titia, additional, Kocks, Janwillem H., additional, Metting, Esther I., additional, Oude Elberink, Hanneke N. G., additional, Peters, Thomas T. A., additional, San Giorgi, Michel R. M., additional, and de Vries, Tjalling W., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Case report of a clinically indolent but morphologically high‐grade cutaneous mast cell tumor in an adult: Atypical cutaneous mastocytoma or mast cell sarcoma?
- Author
-
Wardle, Claire L. W., primary, Oldhoff, J. Marja, additional, Diepstra, Arjan, additional, Valent, Peter, additional, Horny, Hans‐Peter, additional, Oude Elberink, Hanneke N. G., additional, Kluin, Philip M., additional, and Diercks, Gilles F. H., additional
- Published
- 2021
- Full Text
- View/download PDF
7. European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives
- Author
-
Valent, Peter, Arock, Michel, Bonadonna, Patrizia, Brockow, Knut, Broesby-Olsen, Sigurd, Escribano, Luis, Gleixner, Karoline V., Grattan, Clive, Hadzijusufovic, Emir, Hägglund, Hans, Hermine, Olivier, Horny, Hans-Peter, Kluin-Nelemans, Hanneke C., Maurer, Marcus, Niedoszytko, Marek, Nedoszytko, Boguslaw, Nilsson, Gunnar, Oude-Elberink, Hanneke N. G., Orfao, Alberto, Radia, Deepti, Reiter, Andreas, Siebenhaar, Frank, Sotlar, Karl, Sperr, Wolfgang R., Triggiani, Massimo, VanDoormaal, Jaap J., Várkonyi, Judit, Yavuz, Selim, and Hartmann, Karin
- Published
- 2012
- Full Text
- View/download PDF
8. Successful rapid desensitization in a glioma patient with procarbazine‐mediated anaphylaxis
- Author
-
Hutten, Evelien M., primary, Lambeck, Annechien J. A., additional, Dijkstra, Hilda, additional, Nuver, Janine, additional, Oude Elberink, Hanneke N. G., additional, and Van de Ven, Annick A. J. M., additional
- Published
- 2021
- Full Text
- View/download PDF
9. EAACI/GA2LEN/EDF/WAO-Leitlinie für die Definition, Klassifikation, Diagnose und das Management der Urtikaria — konsentierte, deutschsprachige Übersetzung
- Author
-
Zuberbier, Torsten, Aberer, Werner, Asero, Riccardo, Latiff, Amir Hamzah Abdul, Baker, Diane, Ballmer-Weber, Barbara K, Bernstein, Jonathan A, Bindslev-Jensen, Carsten, Brzoza, Zenon, Bedrikow, Roberta Buense, Canonica, Giorgio Walter, Church, Martin K, Craig, Timothy, Danilycheva, Inna Vladimirovna, Dressler, Corinna, Ensina, Luis Felipe, Giménez-Arnau, Ana M, Godse, Kiran, Gonçalo, Margarida, E. H. Grattan, Clive, Hebert, Jacques, Hide, Michihiro, Kaplan, Allen, Kapp, Alexander, Katelaris, Constance H., Kocatürk, Emek, Kulthanan, Kanokvalai, Larenas-Linnemann, Desiree, Leslie, Tabi A., Magerl, Markus, Mathelier-Fusade, Pascale, Meshkova, Raisa Y., Metz, Martin, Nast, Alexander, Nettis, Eustachio, Oude-Elberink, Hanneke N G, Rosumeck, Stefanie, Saini, Sarbjit S, Sánchez-Borges, Mario, Schmid-Grendelmeier, Peter, Staubach, Petra, Sussman, Gordon, Toubi, Elias, Vena, Gino A., Vestergaard, Christian, Wedi, Bettina, Werner, Ricardo N., Zhao, Zuotao, Maurer, Marcus, Brehler, Randolf, Brockow, Knut, Fluhr, Joachim, Grabbe, Jürgen, Hamelmann, Eckard, Hartmann, Karin, Jakob, Thilo, Merk, Hans, Ollert, Markus, Ott, Hagen, Reese, Imke, Ruëff, Franziska, and Werfel, Thomas
- Published
- 2018
10. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
- Author
-
Kluin-Nelemans, Hanneke C., Jawhar, Mohamad, Reiter, Andreas, van Anrooij, Bjorn, Gotlib, Jason, Hartmann, Karin, Illerhaus, Anja, Oude Elberink, Hanneke N. G., Gorska, Aleksandra, Niedoszytko, Marek, Lange, Magdalena, Scaffidi, Luigi, Zanotti, Roberta, Bonadonna, Patrizia, Perkins, Cecelia, Elena, Chiara, Malcovati, Luca, Shoumariyeh, Khalid, von Bubnoff, Nikolas, and Müller, Sabine
- Published
- 2021
- Full Text
- View/download PDF
11. Blinded sensory evaluation of extensively hydrolyzed formulas and amino acid formulas.
- Author
-
de Jong, Nicolette W., Sprikkelman, Aline B., Oude Elberink, Hanneke N. G., Arends, Nicolette J. T., and Vlieg-Boerstra, Berber J.
- Published
- 2014
- Full Text
- View/download PDF
12. Outcomes of apple oral immunotherapy in pollen food allergy syndrome.
- Author
-
Dijkema D, Ruitenbeek MC, Weerstand-Noor K, Oude Elberink HNG, and van de Ven AAJM
- Abstract
Oral immunotherapy with apple induces tolerance for an entire apple (128 g) in patients with pollen food allergy syndrome who previously tolerated a median amount of 4 g of apple., Competing Interests: Disclosure of potential conflict of interest: H. N. G. Oude Elberink’s institution has received consultancy fees from ALK-Abelló; in addition, she has received fees for delivering lectures from Chiesi, ALK-Abelló, and Meda; consultancy fees from ALK-Abelló; research support from Novartis, MEDA Pharma, Mead Johnson, ALK-Abelló, Shire, and Chiesi; and payment for developing educational presentations from ALK-Abelló. A. A. J. M. van de Ven has received fees for delivering lectures for Takeda. The rest of the authors declare that they have no relevant conflicts of interest., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
13. Hereditary Alpha Tryptasemia: Validation of a Single-Well Multiplex Digital Droplet PCR Assay in a Cohort of Symptomatic Patients.
- Author
-
Alheraky A, Wierenga ATJ, Simpelaar A, Hesp LB, Minovic I, Bagheri N, Roozendaal C, Span LFR, Oude Elberink HNG, Kema IP, and Mulder AB
- Subjects
- Humans, Tryptases genetics, Polymerase Chain Reaction, Mast Cells, DNA Copy Number Variations
- Abstract
Background: Hereditary alpha tryptasemia (HαT) has significant prevalence and potential morbidity in the general population. However, it remains largely undiagnosed in routine clinical diagnostics due to low availability of efficient assessment methods. To address this issue, we developed a reliable and efficient single-well multiplex digital droplet PCR assay., Methods: The assay was based on the reconstruction of the TPSAB1 gene through quantification of the ratio of α- and β-tryptase copy number variants (CNV) in a single-well measurement. We performed analytical validation by determining CNV measurement clustering around the expected copy numbers in 281 cases and determined the diagnostic accuracy of basal serum tryptase (BST) to predict HαT and HαT subtypes in 141 symptomatic patients., Results: The assay determined α- and β-tryptase CNVs with an overall accuracy, expressed as a 99% prediction interval, of 0.03 ± 0.27 copy numbers. The optimal BST cutoff level to predict HαT in symptomatic patients, who had no other explanation for relatively high tryptase levels (i.e., no diagnosis of systemic mastocytosis, myeloid neoplasm, or end-stage renal failure), was 9.2 ng/mL (sensitivity: 98.1%; specificity: 96.6%). HαT showed a linear gene-dose effect, with an average gene-dose increase of 7.5 ng/mL per extra α-tryptase gene., Conclusion: Our single-well multiplex digital droplet PCR assay accurately determined HαT and could be implemented as a state-of-the-art routine diagnostic test. The assay demonstrated a strong correlation with BST and the optimal threshold for identifying HαT in symptomatic patients with unexplained high tryptase concentrations was at a BST level of 9.2 ng/mL., (© The Author(s) 2023. Published by Oxford University Press on behalf of Association for Diagnostics & Laboratory Medicine.)
- Published
- 2024
- Full Text
- View/download PDF
14. Vertebral fracture in a 7-year-old boy with indolent systemic mastocytosis.
- Author
-
Bocca-Tjeertes IFA, Boot AM, Brand HK, van Doormaal JJ, and Oude Elberink HNG
- Subjects
- Male, Humans, Child, Mastocytosis, Systemic diagnosis, Spinal Fractures, Mastocytosis
- Published
- 2023
- Full Text
- View/download PDF
15. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives.
- Author
-
Valent P, Hartmann K, Bonadonna P, Sperr WR, Niedoszytko M, Hermine O, Kluin-Nelemans HC, Sotlar K, Hoermann G, Nedoszytko B, Broesby-Olsen S, Zanotti R, Lange M, Doubek M, Brockow K, Alvarez-Twose I, Varkonyi J, Yavuz S, Nilsson G, Radia D, Grattan C, Schwaab J, Gülen T, Oude Elberink HNG, Hägglund H, Siebenhaar F, Hadzijusufovic E, Sabato V, Mayer J, Reiter A, Orfao A, Horny HP, Triggiani M, and Arock M
- Subjects
- Humans, Forecasting, Mast Cells, Mastocytosis diagnosis, Mastocytosis therapy, Mastocytosis, Systemic diagnosis
- Abstract
In 2002, the European Competence Network on Mastocytosis (ECNM) was launched as a multidisciplinary collaborative initiative to increase the awareness and to improve diagnosis and management of patients with mast cell (MC) disorders. The ECNM consists of a net of specialized centers, expert physicians, and scientists who dedicate their work to MC diseases. One essential aim of the ECNM is to timely distribute all available information about the disease to patients, doctors, and scientists. In the past 20 years, the ECNM has expanded substantially and contributed successfully to the development of new diagnostic concepts, and to the classification, prognostication, and treatments of patients with mastocytosis and MC activation disorders. The ECNM also organized annual meetings and several working conferences, thereby supporting the development of the World Health Organization classification between 2002 and 2022. In addition, the ECNM established a robust and rapidly expanding patient registry and supported the development of new prognostic scoring systems and new treatment approaches. In all projects, ECNM representatives collaborated closely with their U.S. colleagues, various patient organizations, and other scientific networks. Finally, ECNM members have started several collaborations with industrial partners, leading to the preclinical development and clinical testing of KIT-targeting drugs in systemic mastocytosis, and some of these drugs received licensing approval in recent years. All these networking activities and collaborations have strengthened the ECNM and supported our efforts to increase awareness of MC disorders and to improve diagnosis, prognostication, and therapy in patients., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
16. EAACI guidelines: Anaphylaxis (2021 update).
- Author
-
Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey LH, Riggioni C, de Silva D, Angier E, Arasi S, Bellou A, Beyer K, Bijlhout D, Bilò MB, Bindslev-Jensen C, Brockow K, Fernandez-Rivas M, Halken S, Jensen B, Khaleva E, Michaelis LJ, Oude Elberink HNG, Regent L, Sanchez A, Vlieg-Boerstra BJ, and Roberts G
- Subjects
- Epinephrine therapeutic use, Humans, Tryptases, Anaphylaxis diagnosis, Anaphylaxis etiology, Anaphylaxis therapy
- Abstract
Anaphylaxis is a clinical emergency which all healthcare professionals need to be able to recognize and manage. The European Academy of Allergy and Clinical Immunology Anaphylaxis multidisciplinary Task Force has updated the 2014 guideline. The guideline was developed using the AGREE II framework and the GRADE approach. The evidence was systematically reviewed and recommendations were created by weighing up benefits and harms. The guideline was peer-reviewed by external experts and reviewed in a public consultation. The use of clinical criteria to identify anaphylaxis is suggested with blood sampling for the later measurement of tryptase. The prompt use of intramuscular adrenaline as first-line management is recommended with the availability of adrenaline autoinjectors to patients in the community. Pharmacokinetic data should be provided for adrenaline autoinjector devices. Structured, comprehensive training for people at risk of anaphylaxis is recommended. Simulation training and visual prompts for healthcare professionals are suggested to improve the management of anaphylaxis. It is suggested that school policies reflect anaphylaxis guidelines. The evidence for the management of anaphylaxis remains mostly at a very low level. There is an urgent need to prioritize clinical trials with the potential to improve the management of patients at risk of anaphylaxis., (© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
17. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review.
- Author
-
Gülen T, Akin C, Bonadonna P, Siebenhaar F, Broesby-Olsen S, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink HNG, Butterfield JH, Sperr WR, Alvarez-Twose I, Horny HP, Sotlar K, Schwaab J, Jawhar M, Zanotti R, Nilsson G, Lyons JJ, Carter MC, George TI, Hermine O, Gotlib J, Orfao A, Triggiani M, Reiter A, Hartmann K, Castells M, Arock M, Schwartz LB, Metcalfe DD, and Valent P
- Subjects
- Diagnosis, Differential, Humans, Mast Cells, Tryptases, Mast Cell Activation Syndrome diagnosis
- Abstract
In recent years, knowledge about mechanisms underlying mast cell activation (MCA) and accumulation in various pathologic conditions increased substantially. In addition, criteria and a classification of MCA syndromes (MCASs) have been set forth. MCAS is defined by typical clinical symptoms, a substantial increase in serum tryptase level during an attack over the patient's baseline tryptase, and a response of the symptoms to drugs targeting mast cells, mediator production, and/or mediator effects. Alternative diagnostic criteria of MCAS have also been suggested, but these alternative criteria often lack specificity and validation. In this report, we critically review the contemporary literature relating to MCAS and compare the specificity, sensitivity, and strength of MCAS-related parameters within proposals to diagnose and classify MCAS and its variants. Furthermore, we highlight the need to apply specific consensus criteria in the evaluation and classification of MCAS in individual patients. This is an urgent and important medical necessity because as an increasing number of patients are being given a misdiagnosis of MCAS based on nonspecific criteria, which contributes to confusion and frustration by patients and caregivers and sometimes may delay recognition and treatment of correct medical conditions that often turn out to be unrelated to MCA., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
18. Successful oral desensitization and reintroduction in selected glioma patients with procarbazine-mediated hypersensitivity.
- Author
-
Van der Valk H, Dijkstra H, Walenkamp A, Schuttelaar MLA, Oude Elberink HNG, and Van de Ven AAJM
- Subjects
- Desensitization, Immunologic, Humans, Procarbazine, Drug Hypersensitivity diagnosis, Drug Hypersensitivity etiology, Drug Hypersensitivity therapy, Glioma drug therapy
- Published
- 2020
- Full Text
- View/download PDF
19. Fracture Risk Reduction by Bisphosphonates in Mastocytosis?
- Author
-
Onnes MC, van Doormaal JJ, van der Veer E, Versluijs JB, Arends S, and Oude Elberink HNG
- Subjects
- Bone Density, Diphosphonates therapeutic use, Humans, Retrospective Studies, Risk Reduction Behavior, Fractures, Bone epidemiology, Fractures, Bone prevention & control, Mastocytosis
- Abstract
Background: Fragility fractures (FFxs) and osteoporosis are frequent manifestations of indolent systemic mastocytosis (ISM). So far, the effect of antiosteoporotic therapy on FFxs has scarcely been investigated., Objective: This study evaluates the long-term effect of bisphosphonate treatment on FFxs, bone mineral density (BMD), and bone resorption in patients with ISM in daily clinical practice., Methods: Patients with ISM who received bisphosphonates because of osteoporosis and/or FFxs were retrospectively analyzed (n = 58). Fractures were recorded by vertebral fracture assessment, X-rays of the thoracolumbar spine, medical records, and a questionnaire. Five-year analysis (n = 30) was made by comparing observed 5-year FFx risk with MastFx-predicted FFx risk for patients with ISM not treated with antiosteoporotic drugs and analyzing 5-year change in BMD and serum collagen C telopeptide (sCTx) Z-scores., Results: During the median follow-up of 7.3 years, 14 of 58 patients suffered 40 FFxs. Five- and 10-year FFx-free survival were 81.9% (standard error [SE], 5.5%) and 67.0% (SE, 7.7%), respectively. FFx risk was significantly higher in patients with previous vertebral FFxs (P = .004), lower femoral BMD at baseline (P = .042), and history of anaphylaxis (P = .028). No 5-year FFx risk reduction could be proven, possibly due to the small sample size. The lumbar BMD Z-score significantly increased from median (interquartile range [IQR]) -2.20 (-2.80 to -1.50) to -1.50 (-2.30 to -0.60) (P < .001, n = 27). The sCTx Z-score decreased from median 0.71 (IQR, -0.59 to 2.39) to -0.95 (-1.30 to -0.16) (P = .008, n = 15)., Conclusion: Bisphosphonates significantly increase BMD and decrease sCTx in patients with ISM. However, FFxs still frequently occur. Especially patients with previous FFxs remain at high risk of new FFxs., (Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
20. AR101 Oral Immunotherapy for Peanut Allergy.
- Author
-
Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, Jones SM, Shreffler WG, Marcantonio A, Zawadzki R, Sher L, Carr WW, Fineman S, Greos L, Rachid R, Ibáñez MD, Tilles S, Assa’ad AH, Nilsson C, Rupp N, Welch MJ, Sussman G, Chinthrajah S, Blumchen K, Sher E, Spergel JM, Leickly FE, Zielen S, Wang J, Sanders GM, Wood RA, Cheema A, Bindslev-Jensen C, Leonard S, Kachru R, Johnston DT, Hampel FC Jr, Kim EH, Anagnostou A, Pongracic JA, Ben-Shoshan M, Sharma HP, Stillerman A, Windom HH, Yang WH, Muraro A, Zubeldia JM, Sharma V, Dorsey MJ, Chong HJ, Ohayon J, Bird JA, Carr TF, Siri D, Fernández-Rivas M, Jeong DK, Fleischer DM, Lieberman JA, Dubois AEJ, Tsoumani M, Ciaccio CE, Portnoy JM, Mansfield LE, Fritz SB, Lanser BJ, Matz J, Oude Elberink HNG, Varshney P, Dilly SG, Adelman DC, and Burks AW
- Subjects
- Administration, Oral, Adolescent, Adult, Age Factors, Allergens adverse effects, Biological Products adverse effects, Biological Products immunology, Child, Child, Preschool, Desensitization, Immunologic adverse effects, Dose-Response Relationship, Immunologic, Double-Blind Method, Female, Gastrointestinal Diseases etiology, Humans, Male, Middle Aged, Plant Proteins adverse effects, Plant Proteins immunology, Young Adult, Allergens administration & dosage, Arachis adverse effects, Biological Products administration & dosage, Desensitization, Immunologic methods, Peanut Hypersensitivity therapy, Plant Proteins administration & dosage
- Abstract
Background: Peanut allergy, for which there are no approved treatment options, affects patients who are at risk for unpredictable and occasionally life-threatening allergic reactions., Methods: In a phase 3 trial, we screened participants 4 to 55 years of age with peanut allergy for allergic dose-limiting symptoms at a challenge dose of 100 mg or less of peanut protein (approximately one third of a peanut kernel) in a double-blind, placebo-controlled food challenge. Participants with an allergic response were randomly assigned, in a 3:1 ratio, to receive AR101 (a peanut-derived investigational biologic oral immunotherapy drug) or placebo in an escalating-dose program. Participants who completed the regimen (i.e., received 300 mg per day of the maintenance regimen for approximately 24 weeks) underwent a double-blind, placebo-controlled food challenge at trial exit. The primary efficacy end point was the proportion of participants 4 to 17 years of age who could ingest a challenge dose of 600 mg or more, without dose-limiting symptoms., Results: Of the 551 participants who received AR101 or placebo, 496 were 4 to 17 years of age; of these, 250 of 372 participants (67.2%) who received active treatment, as compared with 5 of 124 participants (4.0%) who received placebo, were able to ingest a dose of 600 mg or more of peanut protein, without dose-limiting symptoms, at the exit food challenge (difference, 63.2 percentage points; 95% confidence interval, 53.0 to 73.3; P<0.001). During the exit food challenge, the maximum severity of symptoms was moderate in 25% of the participants in the active-drug group and 59% of those in the placebo group and severe in 5% and 11%, respectively. Adverse events during the intervention period affected more than 95% of the participants 4 to 17 years of age. A total of 34.7% of the participants in the active-drug group had mild events, as compared with 50.0% of those in the placebo group; 59.7% and 44.4% of the participants, respectively, had events that were graded as moderate, and 4.3% and 0.8%, respectively, had events that were graded as severe. Efficacy was not shown in the participants 18 years of age or older., Conclusions: In this phase 3 trial of oral immunotherapy in children and adolescents who were highly allergic to peanut, treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose-limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo. (Funded by Aimmune Therapeutics; PALISADE ClinicalTrials.gov number, NCT02635776 .).
- Published
- 2018
- Full Text
- View/download PDF
21. Management around invasive procedures in mastocytosis: An update.
- Author
-
Hermans MAW, Arends NJT, Gerth van Wijk R, van Hagen PM, Kluin-Nelemans HC, Oude Elberink HNG, Pasmans SGMA, and van Daele PLA
- Subjects
- Adrenal Cortex Hormones adverse effects, Anaphylaxis etiology, Anaphylaxis immunology, Anaphylaxis pathology, Anesthesia, General adverse effects, Bone Marrow drug effects, Bone Marrow immunology, Bone Marrow pathology, Contraindications, Female, Histamine Antagonists adverse effects, Humans, Iatrogenic Disease, Male, Mast Cells drug effects, Mast Cells immunology, Mastocytosis, Systemic diagnostic imaging, Mastocytosis, Systemic immunology, Mastocytosis, Systemic pathology, Skin drug effects, Skin immunology, Skin pathology, Stress, Mechanical, Surgical Procedures, Operative adverse effects, Anaphylaxis prevention & control, Contrast Media adverse effects, Mast Cells pathology, Mastocytosis, Systemic therapy, Radiography
- Abstract
Objective: Mastocytosis is a chronic hematologic disorder that is characterized by the accumulation of aberrant mast cells and typically involves the skin and/or bone marrow. Patients with mastocytosis are at increased risk of anaphylaxis. Based on theoretical assumptions, medical procedures requiring general anesthesia or radiocontrast media are deemed hazardous for patients with mastocytosis. The objective of this article is to provide a comprehensive overview of the actual risk of iatrogenic anaphylaxis and provide recommendations for daily practice., Data Sources: Various scientific search engines were used (eg, PubMed and Medline)., Study Selections: Because of the paucity of high-level studies on this topic, all available evidence was considered, including case reports., Results: Reliable data on the incidence of iatrogenic anaphylaxis in mastocytosis are lacking. However, although the incidence as reported in (retrospective) cohort studies is higher than in the general population, it is still lower than commonly anticipated, with an incidence of 5.4% in 1 study. Adequate premedication and avoidance of certain physical stimuli can further decrease this risk by 10-fold. The role of drugs as elicitors of anaphylaxis is perhaps overestimated, and physical stimuli are at least as important in inducing release of mast cell mediators., Conclusion: This article provides practical recommendations for the management of invasive procedures in patients with mastocytosis based on current knowledge of this topic., (Copyright © 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.